|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis.
|
30678628 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y system affects various processes, among others food intake, and is frequently discussed in the context of targeting obesity.
|
31533726 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mechanistically, it is the diminished insulin signaling capacity on central amygdala NPY neurons under combined stress and high-fat-diet conditions that leads to the exaggerated development of obesity.
|
31031093 |
2019 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the mechanism of the effect of topiramate to create a state of obesity is thought to involve the decrease in the levels of NPY and FTO.
|
28914170 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Collectively, these data reveal a marked sex difference in the impact of obesity on the sympathoexcitatory actions of insulin and implicate sexually dimorphic changes in NPY inhibition of SNA in the PVN as one mechanism.
|
30628058 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
As NPY and NPY2R are interesting candidate genes for obesity, we hypothesized that a genetic variation in these genes might be implicated in the pathogenesis of obesity.
|
28857123 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
NPY‑ergic neurons in the central amygdala were activated by chronic cold exposure in mice on HFD via neuronal pathways to decrease BDNF and increase GHRH mRNA expression, possibly contributing to the development of obesity and impairment of glucose homeostasis.
|
30106124 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to compare Y5R mRNA and adipocyte parameters consisting of area, width, height, and perimeter either between obese and non-obese subjects or between subcutaneous and visceral fat as well as to compare between NPY, Y1R, Y2R, and Y5R mRNA expressions in subcutaneous and visceral adipose tissues.
|
29763369 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings suggest that PTX3 plays a key role in the development of obesity by enhancing adipocyte differentiation and lipid synthesis <i>via</i> NPY/NPYR signaling.
|
30105036 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Several studies have shown that obesity is associated with increased levels of NPY in the hypothalamus.
|
28954935 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) is a sympathetic neurotransmitter that has been implicated in various disorders including obesity, gastrointestinal and cardiovascular diseases.
|
29370406 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Abnormal regulation of NPY is involved in the development of a wide range of diseases, including obesity, hypertension, atherosclerosis, epilepsy, metabolic disorders, and many cancers.
|
29310113 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These data illustrate that mild cold stress is a critical factor preventing the development of obesity in Snord116<sup>-/-</sup> mice via the NPY system.
|
27823858 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y (NPY) Y<sub>4</sub> receptor (Y<sub>4</sub>R) is involved in energy homeostasis and considered a potential drug target for the treatment of obesity.
|
28345900 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Loss of neuropeptide Y (NPY) can correct the obesity syndrome of mutant mice lacking of leptin (ob/ob).
|
28864114 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Similarly, mice overexpressing NPY in noradrenergic neurons (OE-NPY<sup>DBH</sup>) display obesity and impaired glucose metabolism.
|
28468933 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because NPY and pporexin are negatively regulated by leptin, these findings suggest that in the intrauterine growth restriction group, the leptin resistance of hypothalamic functions, which is usually caused by diet-induced obesity in adulthood, had already been established in the peri-pubertal period.
|
28321032 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Considering that chronic obesity decreases ArcN NPY content, we propose that the ArcN NPY neuropathway to the PVN and DMH is pivotal in obesity-induced elevations in SNA.
|
28628036 |
2017 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
While in heterozygous mice the adipogenic effect of NPY is important, in homozygous mice inhibition of sympathetic tone leading to decreased lipolytic activity and impaired brown fat function, as well as increased endocannabinoid levels contribute to obesity.
|
26681068 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Few genes such as leptin, leptin receptor encoded by the db (diabetes), pro-opiomelanocortin, AgRP and NPY and melanocortin-4 receptors and insulin-induced gene 2 were linked to obesity.
|
27623943 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
To identify NPY gene-by-stress interaction effects on human obesity, we analyzed the interaction between four NPY SNPs and stress with obesity-related traits, including visceral adipose tissue (VAT).
|
27010740 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In obese males, the rs164147 polymorphism of the NPY gene is associated with leptin, insulin level, HOMA-IR, and an increased risk of MetS and its related phenotypes, such as central obesity and hyperglycemia.
|
27788523 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
No significant interaction between NPY SNP polymorphisms and obesity were detected.
|
27469060 |
2016 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Data were extracted and summary estimates of the association between the NPY variants and obesity were examined.
|
26240981 |
2015 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The objective was to examine the effects of NPY variant rs16147 on central obesity and abdominal fat distribution in response to dietary interventions.
|
26156739 |
2015 |